Pancreatoduodenectomy


Journal

In vivo (Athens, Greece)
ISSN: 1791-7549
Titre abrégé: In Vivo
Pays: Greece
ID NLM: 8806809

Informations de publication

Date de publication:
Historique:
received: 06 09 2019
revised: 20 09 2019
accepted: 23 09 2019
entrez: 31 10 2019
pubmed: 31 10 2019
medline: 14 3 2020
Statut: ppublish

Résumé

Pancreatic cancer remains asymptomatic for a long period of time, being frequently diagnosed when vascular invasion is already present. Such cases are widely known as borderline lesions. The aim of this study was to identify the effectiveness of vascular resection in this subgroup of patients. Fifteen such cases were submitted to surgery with curative intent. Eight cases were diagnosed with borderline resectable lesions with portal vein invasion and were submitted to per primam resection and seven cases were initially diagnosed with arterial invasion and had been initially submitted to neoadjuvant chemotherapy followed by resection. In all cases portal vein resection was needed while in other four cases association of superior mesenteric artery resection was performed. Postoperatively, five patients developed complications requiring reoperation, three of whom died at the end of the first postoperative month. The histopathological studies confirmed the completeness of resection in all cases. Vascular resections in pancreatic cancer resections remain demanding procedures, and are reserved for cases in which a radical resection is feasible.

Sections du résumé

BACKGROUND/AIM OBJECTIVE
Pancreatic cancer remains asymptomatic for a long period of time, being frequently diagnosed when vascular invasion is already present. Such cases are widely known as borderline lesions. The aim of this study was to identify the effectiveness of vascular resection in this subgroup of patients.
PATIENTS AND METHODS METHODS
Fifteen such cases were submitted to surgery with curative intent.
RESULTS RESULTS
Eight cases were diagnosed with borderline resectable lesions with portal vein invasion and were submitted to per primam resection and seven cases were initially diagnosed with arterial invasion and had been initially submitted to neoadjuvant chemotherapy followed by resection. In all cases portal vein resection was needed while in other four cases association of superior mesenteric artery resection was performed. Postoperatively, five patients developed complications requiring reoperation, three of whom died at the end of the first postoperative month. The histopathological studies confirmed the completeness of resection in all cases.
CONCLUSION CONCLUSIONS
Vascular resections in pancreatic cancer resections remain demanding procedures, and are reserved for cases in which a radical resection is feasible.

Identifiants

pubmed: 31662572
pii: 33/6/2303
doi: 10.21873/invivo.11738
pmc: PMC6899095
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2303-2308

Informations de copyright

Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Références

Ann Surg Oncol. 2006 Aug;13(8):1035-46
pubmed: 16865597
In Vivo. 2017 Sep-Oct;31(5):983-989
pubmed: 28882970
Scand J Surg. 2017 Sep;106(3):216-223
pubmed: 28376656
In Vivo. 2018 Jul-Aug;32(4):915-919
pubmed: 29936480
J Natl Compr Canc Netw. 2017 Aug;15(8):1028-1061
pubmed: 28784865
Br J Surg. 2006 Jun;93(6):662-73
pubmed: 16703621
Acta Endocrinol (Buchar). 2018 Jul-Sep;14(3):389-393
pubmed: 31149288
J Gastrointestin Liver Dis. 2012 Sep;21(3):277-84
pubmed: 23012669
CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29
pubmed: 25559415
Croat Med J. 2011 Aug 15;52(4):478-87
pubmed: 21853542
J Gastrointest Surg. 2004 Dec;8(8):935-49; discussion 949-50
pubmed: 15585381
Cancer Res. 2014 Jun 1;74(11):2913-21
pubmed: 24840647
J Am Coll Surg. 2010 Feb;210(2):e1-4
pubmed: 20113929
Anticancer Res. 2015 Mar;35(3):1613-8
pubmed: 25750318
Cancer Lett. 2016 Jun 1;375(2):231-237
pubmed: 26970276
World J Surg. 2012 Apr;36(4):884-91
pubmed: 22350478
Dig Dis. 2013;31(1):51-6
pubmed: 23797123
Am J Case Rep. 2015 Sep 19;16:637-44
pubmed: 26386552
J Oncol Pract. 2016 Oct;12(10):915-923
pubmed: 27858562
Surgery. 2014 Jun;155(6):977-88
pubmed: 24856119
Ann Surg. 2015 Jan;261(1):12-7
pubmed: 25599322
Pancreatology. 2016 Jan-Feb;16(1):28-37
pubmed: 26687001
Ann Surg. 2015 Dec;262(6):1092-101
pubmed: 25587814
In Vivo. 2018 Jul-Aug;32(4):911-914
pubmed: 29936479
Ann Surg. 1984 Apr;199(4):418-25
pubmed: 6712317
Cell. 2012 Jan 20;148(1-2):349-61
pubmed: 22265420
Future Oncol. 2019 Jun;15(17):1997-2007
pubmed: 31084373
In Vivo. 2017 Sep-Oct;31(5):979-982
pubmed: 28882969
Ann Surg. 2009 Aug;250(2):187-96
pubmed: 19638912
Br J Surg. 2012 Aug;99(8):1027-35
pubmed: 22569924
Chirurgia (Bucur). 2010 May-Jun;105(3):355-9
pubmed: 20726301
J Gastrointest Surg. 2015 Dec;19(12):2264-8
pubmed: 26423804
Nature. 2010 Oct 28;467(7319):1114-7
pubmed: 20981102
Cancer. 1980 Nov 1;46(9):1945-9
pubmed: 7427900

Auteurs

Nicolae Bacalbasa (N)

"Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
"I. Cantacuzino" Clinical Hospital, Bucharest, Romania.
"Fundeni" Clinical Institute - Center of Excellence in Translational Medicine, Bucharest, Romania.

Irina Balescu (I)

"Ponderas" Academic Hospital, Bucharest, Romania irina.balescu@ponderas-ah.ro.

Simona Dima (S)

"Fundeni" Clinical Institute - Center of Excellence in Translational Medicine, Bucharest, Romania.

Adina Croitoru (A)

"Fundeni" Clinical Institute - Center of Excellence in Translational Medicine, Bucharest, Romania.
"Titu Maiorescu" University, Bucharest, Romania.

Vladislav Brasoveanu (V)

"Fundeni" Clinical Institute - Center of Excellence in Translational Medicine, Bucharest, Romania.
"Titu Maiorescu" University, Bucharest, Romania.

Mihaela Vilcu (M)

"Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
"I. Cantacuzino" Clinical Hospital, Bucharest, Romania.

Iulian Brezean (I)

"Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
"I. Cantacuzino" Clinical Hospital, Bucharest, Romania.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH